A study of microwave ablation for small cell lung cancer

Purpose: To reveal the survival and safety of percutaneous microwave ablation (MWA) combined with chemoradiotherapy (CRT) in treating small cell lung cancer (SCLC). Materials and Methods: Clinical data of 48 SCLC patients who underwent MWA were retrospectively collected; survival and incidence of ma...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and therapeutics 2022-04, Vol.18 (2), p.399-404
Main Authors: Wang, Jiao, Hu, Likuan, Yang, Xia, Ye, Xin, Ni, Yang, Meng, Min, Huang, Guanghui, Zhang, Tiehong, Li, Wenhong, Han, Xiaoying, Wei, Zhigang, Dai, Jianjian, Zou, Zhigeng
Format: Article
Language:English
Subjects:
Ablation
Ablation (Surgery)
Cancer
Care and treatment
Chemotherapy
Combined modality therapy
Humans
Lung cancer
Lung cancer, Small cell
Lung Neoplasms - radiotherapy
Lung Neoplasms - surgery
Methods
Microwaves - adverse effects
Patient outcomes
Radiofrequency Ablation - adverse effects
Radiotherapy
Retrospective Studies
Small Cell Lung Carcinoma - radiotherapy
Small Cell Lung Carcinoma - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c548v-3fd3b9bce2db00b905bea74f84934b3ce71d4edd36d78cf807cb81cdbd908d253
cites cdi_FETCH-LOGICAL-c548v-3fd3b9bce2db00b905bea74f84934b3ce71d4edd36d78cf807cb81cdbd908d253
container_end_page 404
container_issue 2
container_start_page 399
container_title Journal of cancer research and therapeutics
container_volume 18
creator Wang, Jiao
Hu, Likuan
Yang, Xia
Ye, Xin
Ni, Yang
Meng, Min
Huang, Guanghui
Zhang, Tiehong
Li, Wenhong
Han, Xiaoying
Wei, Zhigang
Dai, Jianjian
Zou, Zhigeng
description Purpose: To reveal the survival and safety of percutaneous microwave ablation (MWA) combined with chemoradiotherapy (CRT) in treating small cell lung cancer (SCLC). Materials and Methods: Clinical data of 48 SCLC patients who underwent MWA were retrospectively collected; survival and incidence of major complications were analyzed. Results: Totally, 48 SCLC patients underwent 51 MWA procedures. The median overall survival (OS) for all SCLC was 27.0 months (95% confidence interval 22.4-31.6 months). The OS of limited-stage (LS-SCLC) was longer than the extensive-stage (ES-SCLC) (median 48.0 months vs. 25.0 months, P = 0.022). The OS of SCLC with tumor diameter ≤3.0 cm was longer than that of tumor diameter >3.0 cm (median 48.0 months vs. 27.0 months, P = 0.041). For LS-SCLC, the 1-, 2-, 3-, and 5-year survival rate was 91.67%, 72.22%, 66.67%, and 61.11%, respectively. For ES-SCLC, the 1-, 2-, and 3-year survival rates were 83.33%, 50.0%, and 8.33%. Major complications included pneumothorax needing tube placement (29.4%), rarely arrhythmia (2.0%), empyema (2.0%), pulmonary fungal infection (2.0%), and shingles (2.0%). Conclusion: For SCLC patients, who received MWA combined with CRT, OS of LS-SCLC and tumor diameter ≤3.0 cm was better than that of the ES-SCLC and tumor diameter >3.0 cm. For inoperable SCLC, MWA was safe.
doi_str_mv 10.4103/jcrt.jcrt_1965_21
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2672317631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A704933755</galeid><sourcerecordid>A704933755</sourcerecordid><originalsourceid>FETCH-LOGICAL-c548v-3fd3b9bce2db00b905bea74f84934b3ce71d4edd36d78cf807cb81cdbd908d253</originalsourceid><addsrcrecordid>eNp1kktr3DAQx0VpaLZpP0AvxdBLL97oZUs6LiF9QGgu7VnoMVq8sa1UsrPk21fOJn2xQTAC8fvPjOY_CL0jeM0JZuc7l6b1EjRRbaMpeYFWRClZc8LkS7TCSrCacElP0eucdxg3glL5Cp2ypuUNwe0KyU2Vp9nfVzFUQ-dS3Js7qIztzdTFsQoxVXkwfV85KKGfx23lzOggvUEnwfQZ3j7eZ-jHp8vvF1_qq-vPXy82V7VruLyrWfDMKuuAeouxVbixYAQPkivGLXMgiOfgPWu9kC5ILJyVxHnrFZaeNuwMfTzkvU3x5wx50kOXl2bMCHHOmraCMiJaRgr64T90F-c0lu4WihBKCRd_qK3pQXdjiFMybkmqNwKXtpholrL1EWoLIyTTxxFCV57_4ddH-HI8lLEeFZCDoMw85wRB36ZuMOleE6wXd_WDsX-7WzTvHz842wH8b8WTnQX4dgD2sZ8g5Zt-3kPShb0Z4_75zJoppTf6YRN0DPppE9gvZGW8SQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2671122147</pqid></control><display><type>article</type><title>A study of microwave ablation for small cell lung cancer</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Wang, Jiao ; Hu, Likuan ; Yang, Xia ; Ye, Xin ; Ni, Yang ; Meng, Min ; Huang, Guanghui ; Zhang, Tiehong ; Li, Wenhong ; Han, Xiaoying ; Wei, Zhigang ; Dai, Jianjian ; Zou, Zhigeng</creator><creatorcontrib>Wang, Jiao ; Hu, Likuan ; Yang, Xia ; Ye, Xin ; Ni, Yang ; Meng, Min ; Huang, Guanghui ; Zhang, Tiehong ; Li, Wenhong ; Han, Xiaoying ; Wei, Zhigang ; Dai, Jianjian ; Zou, Zhigeng</creatorcontrib><description>Purpose: To reveal the survival and safety of percutaneous microwave ablation (MWA) combined with chemoradiotherapy (CRT) in treating small cell lung cancer (SCLC). Materials and Methods: Clinical data of 48 SCLC patients who underwent MWA were retrospectively collected; survival and incidence of major complications were analyzed. Results: Totally, 48 SCLC patients underwent 51 MWA procedures. The median overall survival (OS) for all SCLC was 27.0 months (95% confidence interval 22.4-31.6 months). The OS of limited-stage (LS-SCLC) was longer than the extensive-stage (ES-SCLC) (median 48.0 months vs. 25.0 months, P = 0.022). The OS of SCLC with tumor diameter ≤3.0 cm was longer than that of tumor diameter &gt;3.0 cm (median 48.0 months vs. 27.0 months, P = 0.041). For LS-SCLC, the 1-, 2-, 3-, and 5-year survival rate was 91.67%, 72.22%, 66.67%, and 61.11%, respectively. For ES-SCLC, the 1-, 2-, and 3-year survival rates were 83.33%, 50.0%, and 8.33%. Major complications included pneumothorax needing tube placement (29.4%), rarely arrhythmia (2.0%), empyema (2.0%), pulmonary fungal infection (2.0%), and shingles (2.0%). Conclusion: For SCLC patients, who received MWA combined with CRT, OS of LS-SCLC and tumor diameter ≤3.0 cm was better than that of the ES-SCLC and tumor diameter &gt;3.0 cm. For inoperable SCLC, MWA was safe.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/jcrt.jcrt_1965_21</identifier><identifier>PMID: 35645106</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Ablation ; Ablation (Surgery) ; Cancer ; Care and treatment ; Chemotherapy ; Combined modality therapy ; Humans ; Lung cancer ; Lung cancer, Small cell ; Lung Neoplasms - radiotherapy ; Lung Neoplasms - surgery ; Methods ; Microwaves - adverse effects ; Patient outcomes ; Radiofrequency Ablation - adverse effects ; Radiotherapy ; Retrospective Studies ; Small Cell Lung Carcinoma - radiotherapy ; Small Cell Lung Carcinoma - surgery</subject><ispartof>Journal of cancer research and therapeutics, 2022-04, Vol.18 (2), p.399-404</ispartof><rights>COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd.</rights><rights>2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c548v-3fd3b9bce2db00b905bea74f84934b3ce71d4edd36d78cf807cb81cdbd908d253</citedby><cites>FETCH-LOGICAL-c548v-3fd3b9bce2db00b905bea74f84934b3ce71d4edd36d78cf807cb81cdbd908d253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2671122147?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25751,27922,27923,37010,37011,44588</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35645106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Jiao</creatorcontrib><creatorcontrib>Hu, Likuan</creatorcontrib><creatorcontrib>Yang, Xia</creatorcontrib><creatorcontrib>Ye, Xin</creatorcontrib><creatorcontrib>Ni, Yang</creatorcontrib><creatorcontrib>Meng, Min</creatorcontrib><creatorcontrib>Huang, Guanghui</creatorcontrib><creatorcontrib>Zhang, Tiehong</creatorcontrib><creatorcontrib>Li, Wenhong</creatorcontrib><creatorcontrib>Han, Xiaoying</creatorcontrib><creatorcontrib>Wei, Zhigang</creatorcontrib><creatorcontrib>Dai, Jianjian</creatorcontrib><creatorcontrib>Zou, Zhigeng</creatorcontrib><title>A study of microwave ablation for small cell lung cancer</title><title>Journal of cancer research and therapeutics</title><addtitle>J Cancer Res Ther</addtitle><description>Purpose: To reveal the survival and safety of percutaneous microwave ablation (MWA) combined with chemoradiotherapy (CRT) in treating small cell lung cancer (SCLC). Materials and Methods: Clinical data of 48 SCLC patients who underwent MWA were retrospectively collected; survival and incidence of major complications were analyzed. Results: Totally, 48 SCLC patients underwent 51 MWA procedures. The median overall survival (OS) for all SCLC was 27.0 months (95% confidence interval 22.4-31.6 months). The OS of limited-stage (LS-SCLC) was longer than the extensive-stage (ES-SCLC) (median 48.0 months vs. 25.0 months, P = 0.022). The OS of SCLC with tumor diameter ≤3.0 cm was longer than that of tumor diameter &gt;3.0 cm (median 48.0 months vs. 27.0 months, P = 0.041). For LS-SCLC, the 1-, 2-, 3-, and 5-year survival rate was 91.67%, 72.22%, 66.67%, and 61.11%, respectively. For ES-SCLC, the 1-, 2-, and 3-year survival rates were 83.33%, 50.0%, and 8.33%. Major complications included pneumothorax needing tube placement (29.4%), rarely arrhythmia (2.0%), empyema (2.0%), pulmonary fungal infection (2.0%), and shingles (2.0%). Conclusion: For SCLC patients, who received MWA combined with CRT, OS of LS-SCLC and tumor diameter ≤3.0 cm was better than that of the ES-SCLC and tumor diameter &gt;3.0 cm. For inoperable SCLC, MWA was safe.</description><subject>Ablation</subject><subject>Ablation (Surgery)</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Combined modality therapy</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung cancer, Small cell</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Lung Neoplasms - surgery</subject><subject>Methods</subject><subject>Microwaves - adverse effects</subject><subject>Patient outcomes</subject><subject>Radiofrequency Ablation - adverse effects</subject><subject>Radiotherapy</subject><subject>Retrospective Studies</subject><subject>Small Cell Lung Carcinoma - radiotherapy</subject><subject>Small Cell Lung Carcinoma - surgery</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp1kktr3DAQx0VpaLZpP0AvxdBLL97oZUs6LiF9QGgu7VnoMVq8sa1UsrPk21fOJn2xQTAC8fvPjOY_CL0jeM0JZuc7l6b1EjRRbaMpeYFWRClZc8LkS7TCSrCacElP0eucdxg3glL5Cp2ypuUNwe0KyU2Vp9nfVzFUQ-dS3Js7qIztzdTFsQoxVXkwfV85KKGfx23lzOggvUEnwfQZ3j7eZ-jHp8vvF1_qq-vPXy82V7VruLyrWfDMKuuAeouxVbixYAQPkivGLXMgiOfgPWu9kC5ILJyVxHnrFZaeNuwMfTzkvU3x5wx50kOXl2bMCHHOmraCMiJaRgr64T90F-c0lu4WihBKCRd_qK3pQXdjiFMybkmqNwKXtpholrL1EWoLIyTTxxFCV57_4ddH-HI8lLEeFZCDoMw85wRB36ZuMOleE6wXd_WDsX-7WzTvHz842wH8b8WTnQX4dgD2sZ8g5Zt-3kPShb0Z4_75zJoppTf6YRN0DPppE9gvZGW8SQ</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Wang, Jiao</creator><creator>Hu, Likuan</creator><creator>Yang, Xia</creator><creator>Ye, Xin</creator><creator>Ni, Yang</creator><creator>Meng, Min</creator><creator>Huang, Guanghui</creator><creator>Zhang, Tiehong</creator><creator>Li, Wenhong</creator><creator>Han, Xiaoying</creator><creator>Wei, Zhigang</creator><creator>Dai, Jianjian</creator><creator>Zou, Zhigeng</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20220401</creationdate><title>A study of microwave ablation for small cell lung cancer</title><author>Wang, Jiao ; Hu, Likuan ; Yang, Xia ; Ye, Xin ; Ni, Yang ; Meng, Min ; Huang, Guanghui ; Zhang, Tiehong ; Li, Wenhong ; Han, Xiaoying ; Wei, Zhigang ; Dai, Jianjian ; Zou, Zhigeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c548v-3fd3b9bce2db00b905bea74f84934b3ce71d4edd36d78cf807cb81cdbd908d253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Ablation</topic><topic>Ablation (Surgery)</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Combined modality therapy</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung cancer, Small cell</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Lung Neoplasms - surgery</topic><topic>Methods</topic><topic>Microwaves - adverse effects</topic><topic>Patient outcomes</topic><topic>Radiofrequency Ablation - adverse effects</topic><topic>Radiotherapy</topic><topic>Retrospective Studies</topic><topic>Small Cell Lung Carcinoma - radiotherapy</topic><topic>Small Cell Lung Carcinoma - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Jiao</creatorcontrib><creatorcontrib>Hu, Likuan</creatorcontrib><creatorcontrib>Yang, Xia</creatorcontrib><creatorcontrib>Ye, Xin</creatorcontrib><creatorcontrib>Ni, Yang</creatorcontrib><creatorcontrib>Meng, Min</creatorcontrib><creatorcontrib>Huang, Guanghui</creatorcontrib><creatorcontrib>Zhang, Tiehong</creatorcontrib><creatorcontrib>Li, Wenhong</creatorcontrib><creatorcontrib>Han, Xiaoying</creatorcontrib><creatorcontrib>Wei, Zhigang</creatorcontrib><creatorcontrib>Dai, Jianjian</creatorcontrib><creatorcontrib>Zou, Zhigeng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Jiao</au><au>Hu, Likuan</au><au>Yang, Xia</au><au>Ye, Xin</au><au>Ni, Yang</au><au>Meng, Min</au><au>Huang, Guanghui</au><au>Zhang, Tiehong</au><au>Li, Wenhong</au><au>Han, Xiaoying</au><au>Wei, Zhigang</au><au>Dai, Jianjian</au><au>Zou, Zhigeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A study of microwave ablation for small cell lung cancer</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><addtitle>J Cancer Res Ther</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>18</volume><issue>2</issue><spage>399</spage><epage>404</epage><pages>399-404</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>Purpose: To reveal the survival and safety of percutaneous microwave ablation (MWA) combined with chemoradiotherapy (CRT) in treating small cell lung cancer (SCLC). Materials and Methods: Clinical data of 48 SCLC patients who underwent MWA were retrospectively collected; survival and incidence of major complications were analyzed. Results: Totally, 48 SCLC patients underwent 51 MWA procedures. The median overall survival (OS) for all SCLC was 27.0 months (95% confidence interval 22.4-31.6 months). The OS of limited-stage (LS-SCLC) was longer than the extensive-stage (ES-SCLC) (median 48.0 months vs. 25.0 months, P = 0.022). The OS of SCLC with tumor diameter ≤3.0 cm was longer than that of tumor diameter &gt;3.0 cm (median 48.0 months vs. 27.0 months, P = 0.041). For LS-SCLC, the 1-, 2-, 3-, and 5-year survival rate was 91.67%, 72.22%, 66.67%, and 61.11%, respectively. For ES-SCLC, the 1-, 2-, and 3-year survival rates were 83.33%, 50.0%, and 8.33%. Major complications included pneumothorax needing tube placement (29.4%), rarely arrhythmia (2.0%), empyema (2.0%), pulmonary fungal infection (2.0%), and shingles (2.0%). Conclusion: For SCLC patients, who received MWA combined with CRT, OS of LS-SCLC and tumor diameter ≤3.0 cm was better than that of the ES-SCLC and tumor diameter &gt;3.0 cm. For inoperable SCLC, MWA was safe.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>35645106</pmid><doi>10.4103/jcrt.jcrt_1965_21</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0973-1482
ispartof Journal of cancer research and therapeutics, 2022-04, Vol.18 (2), p.399-404
issn 0973-1482
1998-4138
language eng
recordid cdi_proquest_miscellaneous_2672317631
source Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects Ablation
Ablation (Surgery)
Cancer
Care and treatment
Chemotherapy
Combined modality therapy
Humans
Lung cancer
Lung cancer, Small cell
Lung Neoplasms - radiotherapy
Lung Neoplasms - surgery
Methods
Microwaves - adverse effects
Patient outcomes
Radiofrequency Ablation - adverse effects
Radiotherapy
Retrospective Studies
Small Cell Lung Carcinoma - radiotherapy
Small Cell Lung Carcinoma - surgery
title A study of microwave ablation for small cell lung cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A33%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20study%20of%20microwave%20ablation%20for%20small%20cell%20lung%20cancer&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Wang,%20Jiao&rft.date=2022-04-01&rft.volume=18&rft.issue=2&rft.spage=399&rft.epage=404&rft.pages=399-404&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/jcrt.jcrt_1965_21&rft_dat=%3Cgale_proqu%3EA704933755%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c548v-3fd3b9bce2db00b905bea74f84934b3ce71d4edd36d78cf807cb81cdbd908d253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2671122147&rft_id=info:pmid/35645106&rft_galeid=A704933755&rfr_iscdi=true